Research Group

2010 Open Session of the EuFMD Standing Technical Committee

Vienna, Austria

29 September- 1 October 2010

The Global Control of FMD
New Tools and Challenges for Progressive Control

Agenda

Report without Appendices

Report with Appendices

List of participants

Appendixes

Day 1

3. Frenkel Lecture: Integrated procedures to assess FMD vaccine quality and herd immunity in Argentina

5a. Introduction to the Progressive Control Pathway Session

5b. PCP and regional roadmaps towards a common framework for long-term action against FMD at national and regional levels

6. OIE - on the PCP in Relation to OIE Norms on FMD

7. PCP Stage 1 : Achieving Stage 1. Lessons from West Eurasia

8. PCP Stage 2: Monitoring control versus eradication strategies

9. PCP Stage 3 to 4: Achieving freedom, example of Thrace region

10. PCP Stage 4 & 5: Disease free regions: maintaining freedom - what can be improved?

11. Keynote: FMD risk assessment, threat detection

12. Inter-epidemic periods in West Eurasia: are major FMD epidemic predictable

13. Assessing the threat to Europe from global FMD viral pools: a tool to inform antigen priorities for vaccine bank storess

14. Update on the disease bioportal project at UC Davis

15. Custom-Engineered Chimeric FMD vaccine elicits protective immune responses in pigs

16. Production of a safe EMCV-FMDV recombinant vaccine against FMD

17. Recombinant aphtovirus chimera of the glycoprotein of vesicular stomatitis virus evalluated as DNA and protein-based vaccines in mice and cattle

18. Characterisation of the T-dependent and T-independent immune responses in cattle

20. Freezing of formulated FMDV vaccines and vaccines banks: Potential for a faster response in emergency situations

21. Thermostability and infectious properties of a FMD type A virus with a partially deleted VP1 G-H loop

22. Confidence in indirect assessment of FMD vaccine potency and vaccine matching by percentage of expected protection

23. In vitro alternatives for FMD virus challenge in the PD50 vaccine potency test are serotype-dependent

24. Development of an In Process Control Filtration-Assisted Chemiluminometric Immunoassay to Quantify Foot and Mouth Disease virus (FMDV) Non Capsid Proteins in Vaccine Antigen Batches

25. Effect of Thiomersal on dissociation of intact (146S) FMDV virions into 12S particles

Day 2

26. Policy and disease containment strategies in FMD: Living with uncertainty

27. Foot-and-mouth disease control in endemic settings: combining epidemiology, risk assessment and value chains analysis to identify risk control points

28. Using antigenic data on the FMDV capsid for the selection of new vaccine candidates for the SAT types

29. Identifying epitopes and quantifying their role in loss of cross-neutralization

30. Evaluation of cross-protection between O1 Manisa and O1 Campos in cattle vaccinated with O1 Manisa vaccines

31. Sampling, shipping, organisation and testing of inactivated samples to take advantage of molecular analysis Methods

32. Sequence based antigenic characterisation of serotype A FMD viruses from the Middle East

33. Mapping the antigenic variation of FMD virus serotype A

34. Clinical protection, sub-clinical infection and persistence following vaccination with different payloads of O1 Manisa vaccine and challenge in sheep and goats

35. Progressive Control Pathway and serological surveys: Methodological approach to samplingr

36. Seromonitoring for FMD in PCP stage 1: the choice between a random or targeted sampling design?

37. Incorporating descriptive epidemiologu and the livestock network into FMD Progressive Control Pathway to identify risk hotspots and critical control points

38. Conceptual framework for the evaluation of the economic impact of FMD in small holders livestock systems of the Andean region

39. FMDV surveillance in Ethiopia during 2007-2010 towards national control pathway in risk reduction approach

40. Sero-surveillance in the PCP of FMD - Experiences from West Eurasia

41. Quantitative single serum dilution liquid phase Elisa for the Assessment of herd immunity and expectancy of protection against FMD virus in vaccinated cattle

42. Can evaluation methods used for human vaccination programmes be used to improve the control of foot and mouth disease (FMD)?

43. FMDV Genotype definitions and nomenclature

44. Full genome sequence analysis of FMD viruses in Western Eurasia

45.Inter- and intra-herd sequence variability of foot-and-mouth disease viruses recovered during the 2007 UK outbreak

46. Can next generation sequencing be used to unravel fine scale FMDV population dynamics?

47. Keynote: Diagnostics

48. Rescue of highly pathogenic FMD viruses from preserved viral RNA samples collected in Pakistan and Afghanistan

49. Development of a FMD diagnostic multiple bead immunoassay

50. A simple antigen detection Elisa Kit for FMDV serotypes O,A,C, and ASIA1

51. FMD and SVD combined proficiency scheme studies 2009 and 2010 - Virology and overview

52. Use of Priochek® FMDV-NS Elisa and Priocheck® FMDV type O Elisa in Uganda

53. Evaluation of lateral flow device ‘SVANOVA’ for detection of FMDV during the course of infection

55. Diagnostic performance of two commercially available cell viability assays in FMD research

57. Comparison of two ONE-STEP REAL-TIME RT-PCR assays for FMDV diagnosis

58. Comparison of tests that detect Persistent FMDV Infection in cattle

60. Characteristics of some FMD outbreaks in Iran

62. FMDV-A/IRN/2005 endemics in WestEurasia: estimation of coascelent events in the population history

63. Molecular investigation of recent outbreak of the type O FMD Iran

64. Modelling of FMD of Evolution in I.R. Iran since 2006

65. Detection of FMDV in carrier buffalo in South East Asia

66. FMD NSP-seroprevalence in large ruminants in 5 Egyptian governorates under vaccination control – analytical results

67. FMD NSP-seroprevalence in large ruminants in 5 Egyptian governorates under vaccination control – descriptive results

68. Factors associated with within-herd transmission of serotype A FMD virus in Argentina, 2001

69. Temporal, spatial and phylogenetic assessment of full-sequenced serotype a FMD viruses from Argentina, 2001

70. Commodity-based trade in ruminant products: potentials and impacts for Sub- Saharan Africa

71. Foot and mouth disease in Mali and West Africa

72. FMD Virus situation in Nigeria

73. Indication of undetected SAT-1 infection after serological surveillance for foot-andmouth disease in Eritrea

74. Antibodies against FMD virus in African buffalo herds in different national parks in Uganda (2001-2008)

75. Bayesian evolutionary analysis of FMD type A virus in Africa

76. A molecular biological study on recent Sudanese FMD virus isolates.

77. A review on FMD viruses collected in Tanzania from 1967 to 2009

78. Descriptive and spatiotemporal analyses of FMD in Tanzania from 2001 to 2006

79. Developing a partnership for FMD research in Southern Africa

DAY 3

80. Quantitative analysis of FMDV secretion and excretion

81. FMD control - learning from the recent events in FMD free countries in Asia - the problems of high density swine/ruminant areas

82. Some elements of disease preparedness for highly contagious emerging and reemerging diseases in Germany

83. Developing and validating simulation models of FMD for informing policy decisionmakers

84. Classic vs. contact network-based control strategies in FMD and other viral epidemics

85. Protective vaccination to combat FMD in Finland - does it pay?

86. Development of a FMD infection model in severe combined immunodeficient mice for the preliminary evaluation of antiviral drugs

87. Induction of type-1 interferon by bovine plamacytoid dentritic cells (pDCs) in response to FMD virus

88. Getting to the Heart of non-epithelial foot-and-mouth disease virus (FMDV) replication

90. Induction of early specific local immune responses in the respiratory tract of FMD-infected cattle

91. Epicollect

92. Applications of REPLIKINS® in FMDV surveillance and vaccine production

93. Real-Time Training for improved FMD diagnosis and response in the field : Lessons learnt